Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy Hongjie HuoYu FengQiong Tang Original Article Open access 04 January 2024 Pages: 397 - 410
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation Chong-Zhi WangChunping WanChun-Su Yuan Original Article 09 January 2024 Pages: 411 - 425
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells Thamir M. MahgoubEmmet J. JordanDenis M. Collins Original Article Open access 16 January 2024 Pages: 427 - 437
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants Romain SechaudHelen GuHans D. Menssen Original Article 25 January 2024 Pages: 439 - 453
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells Alexandr N. ChernovAlexandr V. KimOlga V. Shamova Original Article 27 January 2024 Pages: 455 - 469
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study Bin FanGhassan K. Abou-AlfaHua Yang Original Article Open access 27 January 2024 Pages: 471 - 479
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations Xiaoya MaYujie LiTianbo Jin Original Article 01 February 2024 Pages: 481 - 496
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors Kadriye Bir YücelUguray AydosOzan Yazıcı Original Article 04 March 2024 Pages: 497 - 507
Pharmacology and pharmacokinetics of tazemetostat Marco OrleniJan H. Beumer Brief Report 23 March 2024 Pages: 509 - 517
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report M. BergeJ. S. GiraudB. Blanchet Letter to the Editor 03 November 2023 Pages: 519 - 521
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment Mototsugu OyaShuichi KanekoYutaka Okayama Retraction Note Open access 16 September 2023 Pages: 523 - 523